| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2023: ¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2022: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2021: ¥8,190,000 (Direct Cost: ¥6,300,000、Indirect Cost: ¥1,890,000)
|
|---|
| Outline of Final Research Achievements |
Research was conducted to clarify factors affecting antigen-specific T cells in liver cancer, leading to the development of novel immunotherapy. The following results were obtained: 1) A method was established to generate genetically engineered T cells with antigen-specific T cell receptors (TCRs); 2) Single-cell gene expression analysis was performed using peripheral blood lymphocytes from patients with long-term survival, and molecules involved in immune memory and fatigue resistance of T cells with TCRs specific to hepatocellular carcinoma (HCC) were identified; 3) In a study on the interaction between T cells and other immune cells, we identified changes in the immune response of T cells to HCC that occur in the body after hepatitis C virus elimination.
|
